CORT — CORCEPT THERAPEUTICS INCORPORATED (Healthcare >> Biotechnology)
CORT FAQ
What is CORT's P/E ratio?
CORCEPT THERAPEUTICS INCORPORATED (CORT) currently trades at a P/E ratio of 101.63.
What is CORT's ROE?
CORCEPT THERAPEUTICS INCORPORATED reports a Return on Equity (ROE) of 7.51%.
What is CORT's dividend yield?
CORCEPT THERAPEUTICS INCORPORATED offers a dividend yield of 0.00%.
What is CORT's Deepscope Quality Score?
Deepscope rates CORT's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CORT?
Deepscope's AI Timing Score for CORT is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CORT belong to?
CORCEPT THERAPEUTICS INCORPORATED is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 72.62
Price
-2.27
(-3.03%)
Day Change
|
|
|---|
CORT Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) nhưng Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROE là âm trong năm ngoái.
ROE đang giảm đáng kể
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
1837
|
| Magic Formula Rank by ROE |
1837
|
| Magic Formula Rank by ROIC |
2540
|
| Price | 72.62 |
| PBV / Sector |
12.60 / 4.63
|
| Earning Per Share | 0.43 |
| PE / Sector |
101.63 / 17.43
|
| PEG or PE/Growth / Sector |
53.49 / 0.53
|
| Average 1M Daily Value |
62.59 M
|
| Average 1W Daily Value |
57.91 M
|
| Yếu tố Kỹ thuật |
|
71% |
| Sức khỏe tài chính |
|
41% |
| Khả năng kiếm lợi nhuận |
|
58% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-06 09:08:49 |
| Symbol | CORT |
| Name | CORCEPT THERAPEUTICS INCORPORATED |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 107.35 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8,039.56 / 8,857.28 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 101 Redwood Shores Parkway, Redwood City, CA, United States, 94065
Phone: 650 327 3270
Website: https://www.corcept.com
Employees: 730
Sector: Healthcare >> Biotechnology
Description: Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google